Loading...
Lapatinib plus capecitabine in treating HER2-positive advanced breast cancer: efficacy, safety, and biomarker results from Chinese patients
Overexpression of human epidermal growth factor receptor-2 (HER2) in metastatic breast cancer (MBC) is associated with poor prognosis. This single-arm open-label trial (EGF109491; NCT00508274) was designed to confirm the efficacy and safety of lapatinib in combination with capecitabine in 52 heavily...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Sun Yat-sen University Cancer Center
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4013397/ https://ncbi.nlm.nih.gov/pubmed/21527065 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5732/cjc.010.10507 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|